WO2019040106A3 - Composés, sels associés et méthodes pour le traitement de maladies - Google Patents

Composés, sels associés et méthodes pour le traitement de maladies Download PDF

Info

Publication number
WO2019040106A3
WO2019040106A3 PCT/US2018/000353 US2018000353W WO2019040106A3 WO 2019040106 A3 WO2019040106 A3 WO 2019040106A3 US 2018000353 W US2018000353 W US 2018000353W WO 2019040106 A3 WO2019040106 A3 WO 2019040106A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
compounds
salts
treatment
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/000353
Other languages
English (en)
Other versions
WO2019040106A2 (fr
Inventor
Ethan S. Burstein
Roger Olsson
Karl Erik Jansson
Niklas Patrik SKÖLD
Larisa Yudina WAHLSTRÖM
Henrik Von Wachenfeldt
Magnus Gustav Wilhelm BERGNER
Klaus DREISCH
Kyrylo POPOV
Oleksnadr KOVALENKO
Per Tomas Klingstedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of WO2019040106A2 publication Critical patent/WO2019040106A2/fr
Publication of WO2019040106A3 publication Critical patent/WO2019040106A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés selon les formules décrites dans la description, qui sont utiles pour le traitement de maladies.
PCT/US2018/000353 2017-08-21 2018-08-20 Composés, sels associés et méthodes pour le traitement de maladies Ceased WO2019040106A2 (fr)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201762548304P 2017-08-21 2017-08-21
US201762548309P 2017-08-21 2017-08-21
US201762548311P 2017-08-21 2017-08-21
US201762548314P 2017-08-21 2017-08-21
US201762548316P 2017-08-21 2017-08-21
US201762548305P 2017-08-21 2017-08-21
US201762548312P 2017-08-21 2017-08-21
US62/548,316 2017-08-21
US62/548,311 2017-08-21
US62/548,314 2017-08-21
US62/548,305 2017-08-21
US62/548,312 2017-08-21
US62/548,304 2017-08-21
US62/548,309 2017-08-21

Publications (2)

Publication Number Publication Date
WO2019040106A2 WO2019040106A2 (fr) 2019-02-28
WO2019040106A3 true WO2019040106A3 (fr) 2019-04-18

Family

ID=65439592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/000353 Ceased WO2019040106A2 (fr) 2017-08-21 2018-08-20 Composés, sels associés et méthodes pour le traitement de maladies

Country Status (1)

Country Link
WO (1) WO2019040106A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113214231B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其医疗应用
CN113214289B (zh) * 2020-01-21 2022-10-28 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
WO2021147818A1 (fr) * 2020-01-21 2021-07-29 瀚远医药有限公司 Antagoniste du récepteur 5-ht2a et son application dans le traitement de maladies du système nerveux central
WO2021193790A1 (fr) 2020-03-26 2021-09-30 塩野義製薬株式会社 Dérivé aromatique hétérocyclique présentant une activité de liaison de récepteur de sérotoninergique
CN113549006B (zh) * 2020-04-26 2023-07-21 江苏恩华药业股份有限公司 一种酰胺衍生物及其应用
CN114728933B (zh) * 2020-07-22 2023-06-16 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
CN113004207B (zh) * 2021-03-05 2023-10-17 中国医科大学 Plk4小分子抑制剂的化合物及其应用
US20240208923A1 (en) 2021-03-10 2024-06-27 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
AU2023319750A1 (en) * 2022-08-03 2025-02-13 Luye Innomind Pharma Shijiazhuang Co., Ltd. 5-ht2a receptor inverse agonist, and preparation method therefor and use thereof
CN120076806A (zh) * 2022-09-14 2025-05-30 杰那医疗公司 使用slc6a19功能的螺取代的和其他哌啶抑制剂治疗pku
WO2024259100A2 (fr) * 2023-06-14 2024-12-19 Jnana Therapeutics Inc. Inhibiteur pipéridine de fonction du slc6a19
CN119661404A (zh) * 2023-09-20 2025-03-21 上海科技大学 环烷烃取代胺类衍生物、其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1965805A1 (fr) * 2005-11-25 2008-09-10 Proskelia SAS Dérivés de l'urée utiles comme modulateurs des récepteurs du calcium
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
WO2017015272A1 (fr) * 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Procédés de préparation de n-(4-fluorobenzyl)-n-(1-méthylpipéridin-4-yl)-n'-(4-2-méthylpropyloxy)phénylméthyl)carbamide, son sel de tartrate et sa forme polymorphe c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1965805A1 (fr) * 2005-11-25 2008-09-10 Proskelia SAS Dérivés de l'urée utiles comme modulateurs des récepteurs du calcium
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
WO2017015272A1 (fr) * 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Procédés de préparation de n-(4-fluorobenzyl)-n-(1-méthylpipéridin-4-yl)-n'-(4-2-méthylpropyloxy)phénylméthyl)carbamide, son sel de tartrate et sa forme polymorphe c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUTT, D. ET AL.: "Inverse agonists - What do they mean for psychiatry?", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 27, January 2017 (2017-01-01), pages 87 - 90, XP029884877, DOI: 10.1016/j.euroneuro.2016.11.013 *

Also Published As

Publication number Publication date
WO2019040106A2 (fr) 2019-02-28

Similar Documents

Publication Publication Date Title
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
WO2018112365A3 (fr) Procédés de traitement du cancer colorectal et d&#39;un mélanome en utilisant parabacteroides goldsteinii
CA2900779C (fr) Compositions et methodes de traitement des affections des maladies neurodegeneratives et de myocardiopathies
WO2015073587A3 (fr) Complexes membrane synthétique- récepteur
EP4497474A3 (fr) Procédés de traitement de maladies rhumatismales à l&#39;aide de composés à base de trimétazidine
WO2016037157A3 (fr) Ciblage de l&#39;activité capn9/capns2 en tant que stratégie thérapeutique pour le traitement de la différentiation des myofibroblastes et des pathologies associées
WO2016118951A3 (fr) Inhibiteurs d&#39;itk hétérocycliques pour traiter l&#39;inflammation et le cancer
HK1246286A1 (zh) Lrrk2抑制剂及其制备和使用方法
WO2015148863A3 (fr) Méthodes liées à crispr/cas et compositions pour le traitement de la drépanocytose
EP4282479A3 (fr) Utilisation de pridopidine pour traiter la dépression ou l&#39;anxiété
WO2016172496A8 (fr) Inhibiteurs de lsd1 et leurs utilisations
WO2015066302A3 (fr) Compositions, méthodes d&#39;utilisation et méthodes de traitement
WO2016055797A3 (fr) Composés et compositions pour le traitement ou la prévention d&#39;affections pathologiques associées à l&#39;excès de dépôt de fibrine et/ou à la formation de thrombus
CA2929436C (fr) Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
WO2015197193A3 (fr) Nouvelle utilisation de molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2016046156A8 (fr) Dérivés d&#39;oxopyridine substitués
WO2016004404A3 (fr) Inhibiteurs de gls1 utiles pour le traitement de maladies
WO2016004413A3 (fr) Inhibiteurs de la gls1 pour le traitement de maladies
EP4574832A3 (fr) Promédicaments de dantrolène et leurs procédés d&#39;utilisation
WO2015106215A3 (fr) Compositions pharmaceutiques comprenant le 15-hepe et méthodes de traitement de l&#39;asthme et de pathologies pulmonaires à l&#39;aide desdites compositions
WO2015075062A3 (fr) Procédé de traitement capillaire
WO2019040105A3 (fr) Composés, sels de ces composés et procédés pour le traitement de maladies
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
WO2018211324A8 (fr) Promédicaments pour traiter une maladie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18783159

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18783159

Country of ref document: EP

Kind code of ref document: A2